Plus Therapeutics shares are trading higher by 183% during Thursday's session. The company announced that the FDA accepted ...
Plus Therapeutics (PSTV) announces the U.S. Food and Drug Administration, FDA, has conditionally accepted the Company’s new proprietary name, ...
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback